Amneal wins REMS supplement approvals for two isotretinoin ANDAs, labeling update for valsartan
FDA approved REMS-related supplements for Amneal's isotretinoin capsules and a labeling supplement for its valsartan tablets in early October 2026.
- FDA approved supplement 3 to Amneal Pharms NY's isotretinoin capsule ANDA 216097, a REMS submission, covering strengths of 10mg, 20mg, 25mg, 30mg, 35mg, and 40mg, with a status date of October 7, 2026.1
- FDA approved supplement 38 to Amneal Pharms NY's isotretinoin capsule ANDA 207792, also a REMS submission, covering 10mg, 20mg, 30mg, and 40mg strengths, with a status date of October 7, 2026.2
- FDA approved supplement 22 to Amneal Pharms' valsartan tablet ANDA 204011, a standard-priority labeling submission covering 40mg, 80mg, 160mg, and 320mg strengths, with a status date of October 6, 2026.3
Fact check notes
- Checker's noteThe summary's 'this week' framing is not supported by the sources, which only provide absolute status dates (Oct 6-7, 2026), not a reporting timeframe.
- Checker's noteThe entry treats 'Amneal Pharms NY' (isotretinoin sponsor) and 'Amneal Pharms' (valsartan sponsor) as the same entity without noting the name variation.
- Sentence removed
Amneal Pharms had three ANDA supplements approved by the FDA this week, covering isotretinoin and valsartan.
unsupported: Sources give only status dates (Oct 6-7, 2026), not a reference point establishing 'this week'; the three-supplement count is correct but the timeframe claim is an unverified addition. Also conflates two sponsor name variants (AMNEAL PHARMS NY vs AMNEAL PHARMS) under one name.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.